Vorapaxar + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerosis
Conditions
Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident, Peripheral Arterial Disease
Trial Timeline
Sep 1, 2007 โ Dec 1, 2011
NCT ID
NCT00526474About Vorapaxar + Placebo
Vorapaxar + Placebo is a phase 3 stage product being developed by Merck for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00526474. Target conditions include Atherosclerosis, Ischemia, Myocardial Infarction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02394730 | Phase 1/2 | Completed |
| NCT00527943 | Phase 3 | Terminated |
| NCT00526474 | Phase 3 | Completed |
Competing Products
20 competing products in Atherosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Olmesartan medoxomil + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| Pactimibe sulfate | Daiichi Sankyo | Phase 2/3 | 65 |
| Pactimibe | Daiichi Sankyo | Phase 2 | 52 |
| Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin | Daiichi Sankyo | Phase 3 | 77 |
| Micronized 17B-estradiol | Johnson & Johnson | Phase 2/3 | 65 |
| Rosuvastatin + placebo + aspirin + placebo | AstraZeneca | Approved | 85 |
| Rosuvastatin + Placebo | AstraZeneca | Approved | 85 |
| rosuvastatin + placebo | AstraZeneca | Phase 1 | 33 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 1 | 33 |
| Rosuvastatin + Atorvastatin | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin (5mg๏ผ10mg๏ผ20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 85 |
| Vorapaxar + Placebo + Aspirin + Clopidogrel | Merck | Phase 2 | 52 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| lovastatin | Merck | Phase 2/3 | 65 |
| Ezetimibe + Placebo | Merck | Approved | 85 |
| Vorapaxar + Placebo | Merck | Phase 3 | 77 |
| Niaspan | Merck | Pre-clinical | 23 |
| MK0633 | Merck | Phase 2 | 52 |